



Editorial

Diagnostic Accuracy of the Combined Modality of a Questionnaire and a Portable Device for COPD Case Finding: Experience With the PUMA Questionnaire

Estimates of COPD burden depend on data sources. According to 2021 global burden of diseases data, the total number of COPD patients (including all ages) is estimated to be 213 million, representing a prevalence of 2.7%.¹ On the other hand, the results of a systematic review that included population-based studies conducted across 260 sites in 65 countries estimated a global prevalence of COPD in 2019 of 10.3% among people aged 30–79 years using the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) definition and 7.6% using the lower limit of normal (LLN), which translates to 292.0 million people.² Despite the current availability of broad and clear recommendations from different scientific societies and organizations on when to suspect and how to diagnose COPD, there is still a high underdiagnosis of the disease³ and data from around the world indicate that between 70% and 90% of people with COPD remain undiagnosed,⁴ especially in low- and middle-income countries. Subjects with undiagnosed COPD have a higher symptom burden, poorer quality of life, and worse general health status than age-matched healthy controls.⁵ The rate of exacerbations in undiagnosed COPD is approximately half that seen in patients with diagnosed COPD; however, they use healthcare services equivalently to treat exacerbation events as people with a prior diagnosis of COPD.⁵ They also have a higher risk of death compared to people without COPD.^{6,7}

Patients with COPD are often diagnosed and begin treatment when the disease is already advanced. In fact, there is evidence showing that 44% of incident COPD cases were only diagnosed for the first time when they had a hospitalization related to COPD.⁸ This could perhaps be the reason why undiagnosed and untreated COPD patients show significant healthcare utilization and worse outcomes. Therefore, the question arises whether a specific COPD active case-finding strategy in the at-risk population could reduce the burden of underdiagnosis and improve the prognosis of the disease. Recently, a randomized clinical trial that used case-finding strategies to identify symptomatic individuals with undiagnosed COPD explored the effects of early treatment by a pulmonologist.⁹ A total of 38,353 persons were interviewed, 595 were found to have undiagnosed COPD or asthma and 508 underwent randomization. Regarding the severity of baseline airflow obstruction, the vast majority of undiagnosed COPD or asthma subjects 430/508 (84.6%) had mild to moderate airflow obstruction. The study showed that symptomatic individuals with undiagnosed COPD who received treatment by a pulmonologist and an educator had fewer respi-

ratory illness events over one-year and showed improvement in symptoms, lung function, and quality of life.⁹ These results suggest that case-finding for symptomatic, undiagnosed COPD is feasible and that early treatment was associated with better clinical outcomes.

Case-finding strategies include active or opportunistic case-finding. Active case-finding involves the proactive search for people at increased risk for the condition, often based on the presence of symptoms, whereas opportunistic case-finding involves a passive approach to case identification, and screening of people that occurs when they present to healthcare services for reasons unrelated to the condition.

Different tools have been assessed for COPD case-finding (questionnaires, handheld devices, or a combination of tools).⁵ Results from different studies suggest that although the combined use of a questionnaire and a handheld device is the most effective strategy for identifying people at increased risk for COPD, questionnaires alone remain valuable tools for predicting COPD.^{5,10} Among the COPD risk questionnaires, the Study of Prevalence and Regular Practice, Diagnosis and Treatment, among General Practitioners in Populations at Risk of COPD in Latin America (PUMA questionnaire) is one that has external validations in different populations.^{11–13}

Table 1 shows the PUMA questionnaire performance of COPD case-finding. In Latin American population the PUMA questionnaire has shown acceptable diagnostic accuracy and predictive performance (AUROC=0.76, sensitivity/specificity/numbers needed to screen=74%/65%/4 at the cutoff score ≥ 5).¹¹ Additionally, in Hong Kong a translated Chinese PUMA version (for Cantonese) exhibited similar performance (AUROC=0.753; sensitivity/specificity=77%/63% at the cutoff score ≥ 6).¹³ To date, no study has evaluated the diagnostic accuracy of the combination of the PUMA questionnaire with handheld devices.

In this issue of the Archivos de Bronconeumología, Kang-Cheng Su et al.¹⁴ assessed the accuracy of PUMA questionnaire in combination with peak expiratory flow rate to identify at-risk, undiagnosed COPD patients. The study included 2 stages: translating English to Chinese PUMA (C-PUMA) questionnaire with linguistic validation and psychometric evaluation, followed by clinical validation. C-PUMA demonstrated an acceptable diagnostic accuracy (AUROC=0.749) and the best cutoff score ≥ 6 . PUMA-PEFR model had higher diagnostic accuracy than C-PUMA alone (AUROC, 0.893 vs. 0.749, $p < 0.05$), accounting for a sen-

Table 1
The PUMA Questionnaire Performance Results of COPD Case-Finding.

Case-Finding Tools	Study [Ref.]	Year	Country	Sample Size	Sample Population	Cut-off	Sensitivity %	Specificity %	AUC
Simple PUMA Weighted PUMA	López Varela et al. ¹¹	2016	Argentina, Colombia, Venezuela, Uruguay	1540	≥40 years of age and ≥10 pack-years, or ≥50 pipes per year or ≥50 cigars per year and/or exposure to biomass smoke	≥5	74.2	64.8	0.76
						≥25	76.3	69.3	0.79
Simple PUMA	López Varela et al. ¹²	2019	Hospital Maciel population (Uruguay) PLATINO population (Brasil, México, Chile, Venezuela, Uruguay)	974	≥40 years of age and ≥10 pack-years, or ≥50 pipes per year or ≥50 cigars per year and/or exposure to biomass smoke	≥6	69.9	62.1	0.70
				2512		≥5	51.5	81.6	0.73
Simple PUMA	Au-Doung et al. ¹³	2022	China (Hong Kong)	377	≥40 years of age and ≥10 pack-years	≥6	76.5	63.3	0.75
C-PUMA C-PUMA + PEFR model	Su K-C et al. ¹⁴	2024	China (Taiwan)	240	≥40 years of age and ≥10 pack-years, or ≥50 pipes per year or ≥50 cigars per year and/or exposure to biomass smoke ≥100 h/year and reporting any respiratory symptoms	≥6	77	64	0.75
						≥0.39	78	88	0.89

Definition of abbreviations: AUC = area under the curve; PEFR = peak expiratory flow rate; PUMA = PUMA study questionnaire.

sitivity/specificity/numbers needed to screen of 77%/64%/3 and 79%/88%/2, respectively.¹⁴ A total of 78/240 (32%) were newly diagnosed COPD patients, who were categorized by GOLD grade 1 (37, 47%), grade 2 (34, 44%), and grade 3 (7, 9%) or by GOLD A (60, 8%), B (15, 2%), C (2, 3%) and D (1, 1%).¹⁴ This shows that the vast majority of the newly diagnosed COPD patients had, according to the GOLD stratification, mild to moderate severity of airflow obstruction and a low risk of exacerbation.

These results are of considerable interest because they illustrate again that existing symptom questionnaires such as PUMA, designed for COPD case-finding, are simple and relatively useful to accurately find undiagnosed COPD patients. They also indicate that combined modality using a questionnaire and a handheld device such as peak expiratory flow meters further improved diagnostic accuracy and is the most effective strategy for identifying people at highest risk for COPD. Active case-finding strategy identifies undiagnosed COPD patients with potential clinical benefits of early treatment.

Conflict of Interests

The authors state that they have no conflict of interests.

References

1. Institute for Health Metrics, EvaluationGlobal Burden of Disease. Global Burden of Disease: Global Health Data Exchange. 2019. <https://vizhub.healthdata.org/gbd-results/> [accessed 10.4.24].
2. Adeloje D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10:447–58.
3. Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet L-P, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2018;198:1130–9.
4. Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, et al. Determinants of underdiagnosis of COPD in national and international surveys. *Chest*. 2015;148:971–85.

5. Aaron SD, Montes de Oca M, Celli B, Bhatt SP, Bourbeau J, Criner GJ, et al. Early diagnosis and treatment of chronic obstructive pulmonary disease: the costs and benefits of case finding. *Am J Respir Crit Care Med*. 2024;209:928–37.
6. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. *Lancet Respir Med*. 2017;5:426–34.
7. Gerstein E, Bierbrier J, Whitmore GA, Vandemheen KL, Bergeron C, Boulet L-P, et al. Impact of undiagnosed chronic obstructive pulmonary disease and asthma on symptoms, quality of life healthcare use, and work productivity. *Am J Respir Crit Care Med*. 2023;208:1271–82.
8. Khakban A, Sin DD, FitzGerald JM, Ng R, Zafari Z, McManus B, et al. Ten-year trends in direct costs of COPD: a population-based study. *Chest*. 2015;148:640–6.
9. Aaron SD, Vandemheen KL, Whitmore GA, Bergeron C, Boulet L-P, Côté A, et al. Early diagnosis and treatment of COPD and asthma—a randomized controlled trial. *N Engl J Med*. 2024;390:2061–73.
10. Schnieders E, Ünal E, Winkler V, Dambach P, Louis VR, Horstick O, et al. Performance of alternative COPD case-finding tools: a systematic review and meta-analysis. *Eur Respir Rev*. 2021;30(160):200350.
11. López Varela MV, Montes de Oca M, Rey A, Casas A, Stirbulov R, Di Boscio V. Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America: the PUMA study. *Respirology*. 2016;21:1227–34.
12. Varela MVL, de Oca MM, Wehrmeister FC, Rodriguez C, Ramirez L, Menezes A. External validation of the PUMA COPD diagnostic questionnaire in a general practice sample and the PLATINO study population. *Int J COPD*. 2019;14:1901–11.
13. Au-Doung PLW, Wong CKM, Chan DCC, Chung JWH, Wong SYS, Leung MKW. PUMA screening tool to detect COPD in high-risk patients in Chinese primary care – a validation study. *PLoS ONE*. 2022;17, e0274106.
14. Su KC, Hsiao YH, Ko HK, Chou KT, Jeng TH, Perng DW. The accuracy of PUMA questionnaire in combination with peak expiratory flow rate to identify at-risk undiagnosed COPD patients. *Arch Bronconeumol*. 2024 Jun 21: S0300-2896(24)00234-5.

Maria Montes de Oca^{a,b,*}, Maria Victorina Lopez Varela^c

^a Universidad Central de Venezuela, Caracas, Venezuela

^b Hospital Centro Médico de Caracas, Caracas, Venezuela

^c Universidad de la República, Montevideo, Uruguay

*Corresponding author.

E-mail address: montesdeoca.maria@gmail.com
(M. Montes de Oca).